Street calls of the week: Sep 28 to Oct 2, 2026
Analysts this week focused on valuation discipline, trimming winners and cutting stalled growth stories. Key moves: Wells Fargo downgraded FS KKR (FSK) to Underweight with a $10 target, citing credit risks. Stifel upgraded STAAR Surgical (STAA) to Buy, raising its target to $31. Deutsche Bank downgraded Commerzbank (CBKG) to Hold. Citizens downgraded Foghorn Therapeutics (FHTX) after a drug trial failure. UBS downgraded Gurit Holding (GURN) to Neutral.
How this was made
The 30-second read
Why it matters
The article aggregates several downgrade-driven moves, offering limited new actionable insight.
Market read
Highlights a short‑term pullback in several stocks due to analyst downgrades; no major macro or sector shift.
What to watch
Potential hidden upside from upcoming product pipelines or sector tailwinds not captured in the downgrades.
Background
Weekly analyst call roundup focusing on valuation downgrades after strong prior runs.
Ticker impact
Stifel upgraded STAAR Surgical to Buy, shares rallied 7% on the day.
likely upward pressure as investors price in the upgrade
Upgrade and higher target suggest improved outlook, but limited to short-term move.
Barclays downgraded Mobileye, no share-price move reported.
potential downward pressure pending market reaction
No immediate price move cited; impact uncertain.
Citizens downgraded Foghorn Therapeutics to Market Perform after a failed drug trial, shares fell 18.2%.
likely continued pressure due to lack of pipeline progress
Large intraday drop and negative catalyst make further downside probable.
UBS cut Ormat Technologies to Neutral, stock fell 3.4% on the day.
moderate downward pressure as investors reassess valuation
Small move, but downgrade signals weaker outlook.
BofA cut Fair Isaac to Neutral with a $700 target; no price move reported.
limited impact until price reacts to the rating change
No immediate price reaction cited.
Market effects
Broadly highlights valuation discipline in home‑improvement and biotech sectors.
European and US markets see modest pressure from downgrade wave.
Limited; primarily affects individual stocks rather than macro trends.
Counterpoint
Some investors may view the sharp drops as buying opportunities if fundamentals remain sound.
Key entities
- analystStifel
Upgraded STAAR Surgical.
- analystCitizens
Downgraded Foghorn Therapeutics.
